IIN Inion Oy

RNS Number:2805R
Inion Oy
01 April 2008

                                    Inion Oy
                           ("Inion or the "Company")


Inion to release Interim Management Statements for Q1 and Q3 each financial year


Tampere, Finland and Guildford, UK, 1 April 2008...Inion Oy (LSE: IIN.L) 
("Inion"), a company focused on the development of novel biodegradable medical
implants, announces it will release Interim Management Statements ("IMS") after
three and nine months of each financial year, the first of these to be in April
2008 covering Q1 of 2008.

Pursuant to Section 4(4) of the Regulation of the Finnish Ministry of Finance
(153/2007), a company may issue an IMS if its shares are publicly traded only in
such other member state of the European Economic Area where listed companies are
not required to publish quarterly interim reports for the first three and nine
months of their financial year. This is in accordance with Chapter 2 Section 5C
of the Finnish Securities Market Act and Exemption Order (No. 10/230/2008)
issued by the Finnish Financial Supervision Authority on 28 March 2008.

The statements for Q1 and Q3 are planned for issue in April 2008 and October
each year. The Interim Report for the first half of the year is planned for
issue in August.


For further information, please contact:
Inion Oy                                               Tel: +44 (0)1483 685390
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer


Citigate Dewe Rogerson                                 Tel: +44 (0)207 638 9571
Mark Swallow / David Dible


About Inion (www.inion.com)


Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments.


Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion Optima(TM) family of biomaterials, with properties
tailored for specific surgical applications, in terms of strength, flexibility
and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation.


Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in the
UK and USA, and its head office, R&D and production facilities are in Tampere,
Finland.


This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IMSILFFISAILIIT

Inion Oy (LSE:IIN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Inion Oy (LSE:IIN)
Historical Stock Chart
From Jul 2023 to Jul 2024